Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As Maintenance Therapy For Advanced Non-Small-Cell Lung Cancer: A Meta-analysis Of Randomized Controlled Trials

Objective: The aim of this Meta-analysis is to evaluate the clinical efficacy andsafety of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) asmaintenance therapy for advanced Non-Small-Cell Lung Cancer(NSCLC). Methods: TheCochrane Library, PubMed, Ovid, EMBASE and SCI etc by computer, the randomizedcontrolled trials (randomized control trial, RCT) of EGFR-TKIs as maintenance therapyfor NSCLC were collected by us. The outcomes included objective response rate (ORR),overall survival (OS), progression-free survival (PFS) and toxicities. Relative risk (RR)and hazard ratios (HR) were used for the Meta-analysis and were expressed with95%confidence intervals (95%CI), and the software Comprehensive Meta Analysis software(Version2.0) was used for meta-analyses. Results: Nine trials were included. Metaanalysis indicated that compared with placebo or other programs, the EGFR-TKIs asmaintenance therapy for NSCLC, could increase ORR （OR=1.29， P＜0.01，95%CI=1.10-1.51）,and prolongs PFS （HR=0.74，P＜0.01，95%CI=0.70.10-0.80）andOS（HR=0.90，P＜0.01，95%CI=0.84.10-0.97）,and increased the incidence of diarrheaand rash (P＜0.05). Conclusion: The EGFR-TKIs as maintenance therapy in patients withadvanced NSCLC prolongs RR, OS and PFS.